Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan.
*caveats apply
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
